Showing 1 - 3 results of 3 for search 'Sharon Barrans', query time: 0.03s Refine Results
  1. 1
    A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma.

    A microarray platform-independent classification tool for cell of origin class allows comparative analysis of gene expression in diffuse large B-cell lymphoma. by Matthew A Care, Sharon Barrans, Lisa Worrillow, Andrew Jack, David R Westhead, Reuben M Tooze

    Published 2013-01-01
    Get full text
    Article
  2. 2
    ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial [version 1; peer review: 2 approved]

    ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for... by Andrew Davies, Sharon Barrans, Cathy Burton, Katy Mercer, Joshua Caddy, Fay Chinnery, Laura Day, Diana Fernando, Kirit Ardeshna, Graham Collins, John Radford, Simon Rule, Andrew McMillan, Peter Johnson, Gareth Griffiths

    Published 2020-08-01
    Get full text
    Article
  3. 3
    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial

    Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial by Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, Anthony Lawrie, Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew K. McMillan

    Published 2020-07-01
    Get full text
    Article

Search Tools: